![Will Venetoclax Become The New Standard? [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/7b8bc7d62bbbfefa1a0c2f97a3d163fe.jpg "Will Venetoclax Become The New Standard? [MDS Professional Report]")
Will Venetoclax Become The New Standard? [MDS Professional Report]
Update: 2021-06-02
Description
We will discuss the addition of venetoclax to hypomethylating agents in the treatment of advanced myeloid neoplasms, especially higher-risk myelodysplastic syndromes.We will then report a study testing the efficacy and safety of imetelstat, a new telomerase-inhibitor, in the treatment of patients with lower-risk MDS and anemia following ESA failure.We will then review an interesting therapeutic approach to improve or restore erythroid response by adding lenalidomide to MDS patients treated with erythropoietin but lost the response.Finally, we will return to the "hot" topic of targeting the TP53 mutation, by summarizing an important clinical trial using a TP53 activator.
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
![Treatment of lower-risk MDS [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/59731ffad6896313dd70ce957e619b02.jpg "Treatment of lower-risk MDS [MDS Professional Report]")
![Treatment for Higher-risk MDS [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/474af5f93a7c919181979937a2ea20a4.jpg "Treatment for Higher-risk MDS [MDS Professional Report]")
![Update on Higher-Risk MDS - Lessons from 2023 ASH [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/6fb86eb9669a4d2de76fbe628d3c3231.jpg "Update on Higher-Risk MDS - Lessons from 2023 ASH [MDS Professional Report]")
![MDS in ASH 2021 – Are we already in the molecular era? [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/6f4d6f2e2159220a3406f67f0e6f82f9.jpg "MDS in ASH 2021 – Are we already in the molecular era? [MDS Professional Report]")
Download from Google Play
Download from App Store
United States00:00
00:00
x
